Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Changes in Cutaneous Kaposi's Sarcoma in a Patient Infected With the Human Immunodeficiency Virus: Follow-up to a Controlled Hyperimmunization Trial

Changes in Cutaneous Kaposi's Sarcoma in a Patient Infected With the Human Immunodeficiency... Abstract To the Editor.— Kaposi's sarcoma (KS) is a neoplasm characterized by a proliferation of fibroblastic and microvascular elements with abnormal endothelial cells, extravasated erythrocytes, and spindle-shaped cell infiltration. Kaposi's sarcoma may be systemic with many foci in the mucous membranes, lymph nodes, or visceral organs. In current epidemiology, however, a virulent cutaneous form found on the extremities, trunk, neck, head, or in the oral cavity is a sign of acquired immunodeficiency syndrome (AIDS) in patients infected with the human immunodeficiency virus (HIV).1,2Treatment for KS-AIDS has included chemotherapy, radiation therapy, antiretroviral agents, and immunomodulators in patients with indolent disease.3,4 Because of severely depressed cell-mediated immunity, KS-AIDS patients have a poor tolerance for the myelosuppressive effects of standard antineoplastic agents.5 Recombinant interferon alfa has been the most thoroughly studied of the nonsuppressive immunomodulators, and is most likely to be beneficial in the absence of systemic disease and opportunistic References 1. Safai B, Johnson KG, Myskowski PL, et al. The natural history of Kaposi's sarcoma in the acquired immunodeficiency syndrome . Ann Intern Med . 1985;103:744-750.Crossref 2. Landesman SH, Vieira J. Acquired immune deficiency syndrome (AIDS): a review . Arch Intern Med . 1983;143:2307-2309.Crossref 3. Mitsuyasu RT. AIDS-related Kaposi's sarcoma: a review of its pathogenesis and treatment . Blood Rev . 1988;2:222-231.Crossref 4. Mitsuyasu RT. Kaposi's sarcoma in the acquired immunodeficiency syndrome . Infect Dis Clin North Am . 1988;2:511-523. 5. Sarna G, Mitsuyasu R, Figlin R, Ambersley J, Groopman J. Oral vinzolidine as therapy for Kaposi's sarcoma and carcinomas of lung, breast, and colon/rectum . Cancer Chemother Pharmacol . 1985;14:12-14.Crossref 6. Volberding PA, Mitsuyasu R. Recombinant interferon alpha in the treatment of acquired immune deficiency syndrome-related Kaposi's sarcoma . Semin Oncol . 1985;12:2-6. 7. Mitsuyasu RT. Clinical variants and staging of Kaposi's sarcoma . Semin Oncol . 1987;14:13-18. 8. Pitts FN Jr, Allen AD. Clinical improvement of two patients with T lymphotropic retrovirus diseases after polio vaccine hyperimmunization . Clin Immunol Immunopathol . 1987;43:277-280.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Dermatology American Medical Association

Changes in Cutaneous Kaposi's Sarcoma in a Patient Infected With the Human Immunodeficiency Virus: Follow-up to a Controlled Hyperimmunization Trial

Archives of Dermatology , Volume 126 (6) – Jun 1, 1990

Loading next page...
 
/lp/american-medical-association/changes-in-cutaneous-kaposi-s-sarcoma-in-a-patient-infected-with-the-lgY7g0LnHN
Publisher
American Medical Association
Copyright
Copyright © 1990 American Medical Association. All Rights Reserved.
ISSN
0003-987X
eISSN
1538-3652
DOI
10.1001/archderm.1990.01670300133032
Publisher site
See Article on Publisher Site

Abstract

Abstract To the Editor.— Kaposi's sarcoma (KS) is a neoplasm characterized by a proliferation of fibroblastic and microvascular elements with abnormal endothelial cells, extravasated erythrocytes, and spindle-shaped cell infiltration. Kaposi's sarcoma may be systemic with many foci in the mucous membranes, lymph nodes, or visceral organs. In current epidemiology, however, a virulent cutaneous form found on the extremities, trunk, neck, head, or in the oral cavity is a sign of acquired immunodeficiency syndrome (AIDS) in patients infected with the human immunodeficiency virus (HIV).1,2Treatment for KS-AIDS has included chemotherapy, radiation therapy, antiretroviral agents, and immunomodulators in patients with indolent disease.3,4 Because of severely depressed cell-mediated immunity, KS-AIDS patients have a poor tolerance for the myelosuppressive effects of standard antineoplastic agents.5 Recombinant interferon alfa has been the most thoroughly studied of the nonsuppressive immunomodulators, and is most likely to be beneficial in the absence of systemic disease and opportunistic References 1. Safai B, Johnson KG, Myskowski PL, et al. The natural history of Kaposi's sarcoma in the acquired immunodeficiency syndrome . Ann Intern Med . 1985;103:744-750.Crossref 2. Landesman SH, Vieira J. Acquired immune deficiency syndrome (AIDS): a review . Arch Intern Med . 1983;143:2307-2309.Crossref 3. Mitsuyasu RT. AIDS-related Kaposi's sarcoma: a review of its pathogenesis and treatment . Blood Rev . 1988;2:222-231.Crossref 4. Mitsuyasu RT. Kaposi's sarcoma in the acquired immunodeficiency syndrome . Infect Dis Clin North Am . 1988;2:511-523. 5. Sarna G, Mitsuyasu R, Figlin R, Ambersley J, Groopman J. Oral vinzolidine as therapy for Kaposi's sarcoma and carcinomas of lung, breast, and colon/rectum . Cancer Chemother Pharmacol . 1985;14:12-14.Crossref 6. Volberding PA, Mitsuyasu R. Recombinant interferon alpha in the treatment of acquired immune deficiency syndrome-related Kaposi's sarcoma . Semin Oncol . 1985;12:2-6. 7. Mitsuyasu RT. Clinical variants and staging of Kaposi's sarcoma . Semin Oncol . 1987;14:13-18. 8. Pitts FN Jr, Allen AD. Clinical improvement of two patients with T lymphotropic retrovirus diseases after polio vaccine hyperimmunization . Clin Immunol Immunopathol . 1987;43:277-280.Crossref

Journal

Archives of DermatologyAmerican Medical Association

Published: Jun 1, 1990

References